INDYWIDUALNA PRAKTYKA LEKARSKA KINGA BOBINSKA

The medical center is at the forefront of research in Major Depressive Disorder (MDD), particularly focusing on cases with moderate-to-severe anhedonia. This condition is characterized by a diminished ability to experience pleasure, which significantly impacts the quality of life.

• Adjunctive Therapy with Aticaprant
• Improvement of Depressive Symptoms
• Inadequate Response to SSRIs or SNRIs

Through innovative clinical trials, the center is exploring the efficacy of aticaprant as an adjunctive therapy, aiming to enhance the therapeutic outcomes for patients who do not adequately respond to standard antidepressant treatments.

In addition to acute treatment strategies, the center is dedicated to understanding the long-term safety and tolerability of novel therapeutic agents in the management of Major Depressive Disorder. This research is crucial for ensuring sustained patient well-being over extended periods.

• Long-term Use of Aticaprant
• Safety in Combination with Antidepressants
• Patient Tolerability

The center's commitment to long-term studies provides valuable insights into the sustained use of adjunctive therapies, ensuring that treatments remain effective and safe for patients over time.